| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Moxalactam (also known as latamoxef, Lamoxactam, Festamoxin, LY-127935, 6059-S) is a new synthetic oxa-beta-lactam antibiotic administered intravenously or intramuscularly. It has a broad spectrum of activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria, is particularly active against Enterobacteriaceae and is resistant to hydrolysis by beta-lactamases. Moxalactam has moderate activity against Pseudomonas aeruginosa, but on the basis of present evidence can not be recommended as sole antibiotic treatment of known or suspected pseudomonal infections. Like the related compounds, the cephalosporins, moxalactam is effective in the treatment of complicated urinary tract infections and lower respiratory tract infections caused by Gram-negative bacilli. As moxalactam is also active against Bacteroides fragilis it has considerable potential in the treatment of intra-abdominal infections in patients with normal immunological mechanisms, as well as in immunocompromised patients, when used alone or in combination with other antibiotics. Likewise, its ready penetration into the diseased central nervous system, its high level of activity against Gram-negative bacilli, and the lack of necessity to monitor drug plasma concentrations, indicate its potential value in the treatment of neonatal Gram-negative bacillary meningitis. Further clinical experience is needed before it can be determined whether moxalactam alone can be used in the treatment of conditions for which the aminoglycosides are drugs of choice, but if established as equally effective, moxalactam has the advantage of being devoid of nephrotoxicity. Bleeding is a potentially serious problem, however, particularly in the elderly, malnourished and in the presence of renal impairment.
| Targets |
β-lactam
|
|---|---|
| ln Vitro |
90% of Salmonella species, Morganella morganii, Klebsiella species, Proteus species, Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae, and Escherichia coli strains are inhibited by doxalactam (Latamoxef), including strains resistant to cephalothin and gentamicin at concentrations of less than 1 μg/mL[1].
Acinetobacter species are typically resistant to Moxalactam, while it shows moderate activity against P. aeruginosa and is generally active against other Pseudomonas species[1]. Moxalactam inhibits the production of β-lactamases and does not induce class I β-lactamase. It has demonstrated remarkable stability in vitro against a range of β-lactamases, including that produced by B. fragilis[1]. |
| ln Vivo |
Mice treated with loxalactam (Latamoxef) (0–7.4 mg/mouse; s.c.; once) are resistant to bacterial infections[2].
|
| Animal Protocol |
Animal Model: Four-week-old male strain ICR mice, weighing 18-20 g, bacterial infection model[2]
Dosage: 0-7.4 mg/mouse Administration: Subcutaneous injection, once Result: demonstrated protective action against mice infected with both gram-positive and gram-negative bacteria, with ED50s less than 7.4 mg/mouse. |
| References |
|
| Molecular Formula |
C20H18N6NA2O9S
|
|
|---|---|---|
| Molecular Weight |
564.44
|
|
| Exact Mass |
564.07
|
|
| Elemental Analysis |
C, 42.56; H, 3.21; N, 14.89; Na, 8.15; O, 25.51; S, 5.68
|
|
| CAS # |
64953-12-4
|
|
| Related CAS # |
Moxalactam;64952-97-2
|
|
| Appearance |
Solid powder
|
|
| SMILES |
OC1=CC=C(C(C(N[C@@]2(C(N3[C@@H]2OCC(CSC4=NN=NN4C)=C3C(O[Na])=O)=O)OC)=O)C(O[Na])=O)C=C1
|
|
| InChi Key |
GRIXGZQULWMCLU-HUTAOCTPSA-L
|
|
| InChi Code |
InChI=1S/C20H20N6O9S.2Na/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9;;/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32);;/q;2*+1/p-2/t12?,18-,20+;;/m1../s1
|
|
| Chemical Name |
sodium (6R,7R)-7-(2-carboxylato-2-(4-hydroxyphenyl)acetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~442.92 mM)
H2O : ≥ 50 mg/mL (~88.58 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.08 mg/mL (3.69 mM) Solubility in Formulation 4: 130 mg/mL (230.32 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7717 mL | 8.8583 mL | 17.7167 mL | |
| 5 mM | 0.3543 mL | 1.7717 mL | 3.5433 mL | |
| 10 mM | 0.1772 mL | 0.8858 mL | 1.7717 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA